BRAF and thyroid gland carcinoma: Studies have shown that various agents, including retinoids (vitamin A-derived retinoic acids), the MEK inhibitor selumetinib, and BRAF inhibitors such as vemurafenib and dabrafenib, can induce redifferentiation in thyroid cancer cells [13–16].